Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial

NCT02137226 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02137226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02137226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
January 26, 2015
Completion date
October 18, 2016
Enrollment
645 (actual)
Sites
138

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid